contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-nbs6-system-receives-approval-for-therapy-use-in-canada

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Thank you @Jatast for your clarifying question. Regarding the communication of Brainlab equipment sales, we operate in accordance with our long-term partnership agreement. We aim to communicate these as distributor sales whenever possible, without revealing business secrets, meaning we cannot individually disclose the number of devices sold to Brainlab or Sinaptica at this stage of our agreement. The total number of devices delivered to all our customers (including those delivered to Brainlab) will continue to be reported four times a year, i.e., in Q1 and Q3 business updates, and in H1 and H2 earnings reports. The previous status update regarding device numbers was published in October, in conjunction with the July-September 2025 business update: https://www.nexstim.com/fi/sijoittajat/tiedotteet?publicationId=d8ee8ac6-30d5-455d-b7de-9d865633480d The operating procedure mentioned in the paragraph above relates to press releases, i.e., announcements published in the Press Release category. Press releases, for us as for many other companies, are part of the companies’ marketing communications, and therefore they are flexible and voluntary in terms of format requirements and timing. As a Nasdaq First North company, we also publish regulated company announcements, for which we operate according to Nexstim’s disclosure policy Nexstim - Hallinto ja johtaminen Hopefully, this clarifies the discussion related to communication. We continuously strive to develop this area in cooperation with customers, partners, and the investor community.

Yep. I have strong confidence that this will still be a positive surprise in late winter. As long as the same trend continues until the end, that deals made by distributors in the Brainlab area are not announced. Brainlab has so many sellers and so many ready customers that it would be really strange if not a single deal were made.? Let’s imagine, say, a light 10 devices that weren’t announced, that’s about 3 million

It has also been stated in the interview that as distributors gradually withdraw, inquiries will subsequently be directed to Brainlab regarding the distributors. I don’t believe that inquiries would have ceased during the transition phase; rather, Brainlab has handled those nascent leads like a baton pass, smoothly bringing them to completion with X sales volumes thereafter.

Based on announcements and my calculations, 31 machines have been delivered or ordered this year. Correct me if I calculated wrong. Regarding these speculations about the announcement and sales of diagnostic devices, the last deal that I believe could fall into the Brainlab category was made on October 7th. The others are Nexstim’s own deals. I must say that I am slowly starting to interpret the CEO’s statements in the latest interview to mean that Brainlab’s deals are not being announced. I find it highly unlikely that Brainlab would make zero deals and Nexstim seven. However, Brainlab has been heavily exhibiting the device at trade shows, and the NBS6 device has certainly been anticipated on the market. @Mikko_Karvinen_Nexst, is it possible to clarify/confirm what you said in the interview, that for competitive reasons, Brainlab’s deals or Sinaptica’s machine numbers are only announced in reports?

My theory is as follows: Terveystalo has now purchased two devices to update the NBS 5 devices that came with Recuror to the latest generation of devices, as their own staff will be trained at these two Terveystalo locations. It makes sense to update the devices used for training to the same device version that will be ordered for other clinics in the future. Otherwise, those Recuror’s NBS 5 devices would still have had remaining lifespan. Recuror was founded in 2021 and the devices have a lifespan of 7 years.

It was not directly mentioned in the press release, but the only Finnish private operator that has had two old devices in use has been Recuror, which Terveystalo acquired last summer. So, Terveystalo will also continue with Nexstim devices, and now we await the expansion of treatment offerings to Terveystalo’s locations across Finland. There is undoubtedly demand among insurance and occupational health customers. Additionally, it is likely possible to alleviate the burden on the public sector through service vouchers.

Here is the announcement, gentlemen!                   nexstim.com              Nexstim - Press-release

Nexstim

Nexstim announced on Monday that it had received approval from Health Canada for the marketing and commercial distribution of its NBS6 system for the treatment of Major Depressive Disorder (MDD). The approval expands the commercial potential of Nexstim's latest system beyond the major markets of the US and Europe. 

Translation: Original comment published in Finnish on 5/7/2024 at 7:40 am EEST.
Nexstim&nbsp;<a href="https://www.inderes.se/releases/health-canada-approves-nexstim-nbs-6-system-for-treatment-of-mdd">announced</a> on Monday that it had received approval from Health Canada for the marketing and commercial distribution of its NBS 6 system for the treatment of Major Depressive Disorder (MDD). The approval expands the commercial potential of Nexstim's latest system beyond the major markets of the US and Europe. The company's previous system models have already been available in Canada. The positive news has no immediate impact on our forecasts or our view of the stock.
<h2>Launched last year, NBS6 is gradually replacing older models</h2>
The NBS6 system is Nexstim&rsquo;s latest model. The modular solution is suitable for both therapeutic and diagnostic applications. The system was launched last year in Europe and the US, where it received regulatory approvals for therapeutic use. For diagnostic applications, regulatory approvals are expected this year. To our knowledge, the Canadian approval is the next geographic expansion for the NBS6 after Europe and the United States. Nexstim has sold a few systems to the Canadian market, so commercially this market plays a complementary role for Nexstim. The clear majority of the company's business is in the United States and Europe.

	2023	24e	25e
Revenue	7.2	8.3	10.8
growth-%	-23.9 %	14.8 %	30.3 %
EBIT (adj.)	-1.2	-0.7	0.6
EBIT-% (adj.)	-16.9 %	-8.5 %	5.4 %
EPS (adj.)	-0.18	-0.11	0.07
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	212.9
EV/EBITDA	neg.	1,040.7	85.3

Nexstim NBS6 system receives approval for therapy use in Canada

Launched last year, NBS6 is gradually replacing older models

Key Estimate Figures2024-04-28

Forum discussions